The UK and US have concluded a significant bilateral deal that will preserve zero duties on UK medicine shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to increase expenditure on drugs through the public health system. This move secures that duties on these key products will stay at nothing for a timeframe of three years.
This agreement comes after recent threats to dramatically increase tariffs on patented drug products, with increases floated as high as 100%.
"This deal between the UK reinforces the global environment for new treatments and brings much-needed balance to transatlantic medicine commerce," a release declared.
Economic Impact
Medicines are one of the Britain's most significant goods shipped to the United States, which is by far the primary destination for leading British pharmaceutical firms.
Trade data show that in the year leading up to last September, the UK sold pharmaceutical products totaling billions to the US. This value accounted for a significant portion of total UK exports in that timeframe.
"This deal safeguards employment, boosts capital expenditure and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key British Pledges
The agreement includes several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The percentage drug companies must pay back to the NHS to control costs will be capped at 15%. In the past, repayments were more than twenty percent.
Broader Context
The pact takes place against a long-running dispute between the drug companies and the ministers over spending levels and NHS adoption.
This friction were exacerbated by arguments that American consumers were paying a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its total funding over the last ten years.
